Patrys Limited · ASX:PAB
Patrys — Shareholder Meeting (November 2018)
26 slides from Patrys's shareholder meeting presentation, Nov 22, 2018
Slide 1: Chairman's Address and CEO Presentation at Annual General Meeting
ASX & Media Release Chairman’s Address and CEO Presentation at Annual General Meeting For personal use only Melbourne, Australia; 22 November, 2018: CHAIRMAN’S ADDRESS I am pleased to present these opening remarks to the Patrys Limited 2018 Annual General Meeting. The year ended 30 June 2018 and sub
Slide 2: Chairman's Address: pre-clinical highlights, IgMs, insurance recoveries
Highlights from pre-clinical studies undertaken with PAT-DX1 during the year include: For personal use only PAT-DX1 kills colon cancer cells that lack key DNA repair enzymes (BRAC2) PAT-DX1 is active against primary human glioblastoma explants from patients PAT-DX1 shows efficacy in animal mod
Slide 3: Chairman's Address: team and concluding comments
the insurance claim, Patrys had cash, term deposits and insurance receivables totaling approximately $8.67 million. OUR TEAM For personal use only In large part the success of Patrys is a function of the quality of its management team. The year to- date has seen a number of notable achievements in b
Slide 4: Annual General Meeting 2018
For personal use only Annual General Meeting 2018 Dr James Campbell CEO
Slide 5: Safe Harbour Statement
Safe Harbour Statement For personal use only The following material is for general information purposes only and is not to be relied upon for the making of an investment decision. Any investment in Patrys Limited ACN 123 055 363 (Patrys) is subject to investment risk including the possibility of los
Slide 6: Vision
Vision For personal use only Patrys is a biopharmaceutical company devoted to the development and commercialisation of novel antibody technologies to improve the clinical outcomes for cancer patients CEO Presentation AGM 2018 3
Slide 7: Two platforms, multiple opportunities
Two platforms, multiple opportunities For personal use only • Two Antibody Platforms 1. Deoxymabs – unique positioning at the convergence of two transformative anti-cancer technologies; antibodies and DDR therapies 2. IgMs – completed trials show safety and signals of efficacy, partnered • Different
Slide 8: Development Pipeline
Development Pipeline For personal use only Product Discovery Pre-clinical Phase 1 Phase 2a (Target) PAT-DX1 Licensed from (DNA) Yale University PAT-DX1- Melanoma Licensed from NP Yale University (DNA) Deoxymab Licensed from 5C6 Yale University (DNA) PAT-SC1 Chinese rights (CD55) out-licensed PAT-SM6
Slide 9: Delivery Against 2018 Objectives
Delivery Against 2018 Objectives ✓ For personal use only ✓ DX1-nanoparticle delivery – breast cancer animal data ✓ DX1-nanoparticle tumor localization – breast cancer ✓ DX1 ability to cross the blood brain barrier – brain cancer ✓ DX1 in combination with PARPi – brain cancer animal data ✓ Dynamics o
Slide 10: Nexus of two transformative anti-cancer therapies
Nexus of two transformative anti-cancer therapies For personal use only Antibodies (Abs or mAbs) DNA damage response (DDR) • Bind cancer antigens • Uncorrected DNA damage • Various strategies for use can lead to cancer • Used in brain, breast, CLL, • DDR protects cells from colorectal, head and neck
Slide 11: PAT-DX1 – Humanised Deoxymab 3E10
PAT-DX1 – Humanised Deoxymab 3E10 For personal use only • Optimised for efficacy, manufacturability and novelty • Novel mechanism of action and IP position • Positive results in multiple pre-clinical studies o Kills colon, gliobastoma, breast cancer cells that lack key DNA repair enzymes (BRCA2, PTE
Slide 12: Novel Mechanism of Action
Novel Mechanism of Action For personal use only 3E10 binds to extracellular DNA then is transported across the plasma membrane via the equilibrative nucleoside transporter (ENT2) pathway 3E10 translocates into the nucleus 3E10 binds to nuclear DNA and inhibits DNA repair CEO Presentation AGM 2018 9
Slide 13: Research Partnered with Yale University
Research Partnered with Yale University For personal use only • James E. Hansen, MD (Principal Investigator) • Assistant Professor, Department of Therapeutic Radiology, Yale School of Medicine • Physician-scientist and practicing radiation oncologist specialising in treatment of cancers of the brain
Slide 14: Focussed on Progression to the Clinic
Focussed on Progression to the Clinic For personal use only Triple negative breast cancer PAT-DX1 Progress to clinic Glioblastoma PAT-DX1 + radiotherapy PAT-DX1 + chemotherapy PAT-DX1 conjugation with nanoparticles PAT-DX1 conjugation with other antibodies PAT-DX1 conjugation with radionucleotides P
Slide 15: Targeted Clinical Indications
Targeted Clinical Indications For personal use only • Triple Negative Breast Cancer o 15-20% of the global 1.67 million new cases of breast cancer annually and the most aggressive and difficult to treat o Associated with impaired homologous recombination that makes these cancer cells vulnerable to i
Slide 16: PAT-DX1 in Model of MGMT-Unmethylated GBM Derived from Human Tumour Explants
PAT-DX1 in Model of MGMT-Unmethylated GBM Derived from Human Tumour Explants For personal use only • Dark staining is glioblastoma, light staining is health brain tissue • Translates as survival benefit CEO Presentation AGM 2018 13
Slide 17: PAT-DX1 Nanoparticle Conjugates
PAT-DX1 Nanoparticle Conjugates For personal use only • PAT-DX1 can be linked to PAT-DX1-NP localisation in mice with triple negative breast cancer tumors nanoparticles (NPs) loaded with chemotherapeutic (or other) drugs • PAT-DX1-NPs are preferentially attracted to tumor tissues and deliver payload
Slide 18: Recent Pre-clinical Cancer Antibody Deals
Recent Pre-clinical Cancer Antibody Deals For personal use only Total Up Front Date Tech Seller Buyer (USD) (USD) Feb-14 Nanobody platform Ablynx Merck 6.5B 27 M Checkpoint regulators: GITR, OX40, Jan-15 Agenus Incyte 410M 60M LAG-3 and TIM-3 Aug-15 Anti-GDF15 MAb Aveo Oncology Novartis 326M 15M Oct
Slide 19: IgM Overview
IgM Overview For personal use only • Body’s first line of defence as part of the innate immune response • Demonstrated anti-tumour activity in both mice and humans • Excellent safety profile in humans • reduced side effects • Combination with existing chemotherapeutic treatments potentially without
Slide 20: Initial Therapeutic Candidate, PAT-SC1 – Out-licensed
Initial Therapeutic Candidate, PAT-SC1 – Out-licensed For personal use only • Hefei Co-source licensed rights to PAT-SC1 for China in 2015 • Hefei currently pursuing CHO cell line development work • Orphan designation by the FDA for use in gastric cancer • No other known clinical products targeting
Slide 21: Experienced Board
Experienced Board For personal use only John Read Chairman • Experienced Chairman and Director in public, private and government organisations • Extensive career in venture capital, private equity and commercialisation • Chairman of CVC Limited (ASX: CVC), previously Eildon Capital Limited (ASX:EDC)
Slide 22: Management Team
Management Team For personal use only Melanie Leydin CFO and Company Secretary • Over 25 years experience in the accounting profession with extensive experience in relation to public company responsibilities, including ASX and ASIC compliance, control and implementation of corporate governance, stat
Slide 23: Scientific Advisory Board
Scientific Advisory Board For personal use only Dr Pamela M. Klein • Medical training, then U.S. National Cancer Institute • Vice President, Development at Genentech, led development of a large portfolio of drugs including all the HER (Herceptin, Tarceva, Perjeta), Apoptosis (antibodies and small mo
Slide 24: Financial Snapshot
Financial Snapshot For personal use only Financial Parameter Measurement ASX: PAB 1,073 million shares Daily volume (3 mth ave):* 2.3 million shares Market Capitalization:* $28.8 million Cash held:** $5.6 million Net burn rate: $2.1 million in 2017-18 * Effective 21 November, 2018 ** $5.6 M reported
Slide 25: Looking Ahead
Looking Ahead For personal use only DX1 + radiation – brain cancer animal data Q4 2018/Q1 2019 DX1 – solid cancer (TBC) animal data Q1 2019 DX1 + temazolamide – brain cancer animal data Q1 2019 Partnering of IgM assets H1 2019 Additional studies in relevant animal models of cancer Ongoing Developmen
Slide 26: For Further Information
For Further Information For personal use only Contact Details: Dr. James Campbell Chief Executive Officer and Managing Director Ph: +61 3 9670 3273 Email: info@patrys.com Website: www.patrys.com CEO Presentation AGM 2018 23